TITLE

Co-expression of ER-beta and HER2 associated with poorer prognosis in primary breast cancer

AUTHOR(S)
Qui Wen-sheng; Yue Lu; Ding Ai-ping; Sun Jian; Yao Yang; Shen Zan; Fan Li-hong
PUB. DATE
June 2009
SOURCE
Clinical & Investigative Medicine;Jun2009, Vol. 32 Issue 3, pE250
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: To assess the prognostic value of co-expression of estrogen receptor (ER)-beta and human epidermal growth factor receptor 2 (HER2) in primary breast cancer patients in China. Methods: Tumour specimens from 308 patients undergoing surgery for primary breast cancer were evaluated. Expression of ER-beta and HER-2 was investigated by the immunohistochemistry. Results: 123 patients (40%) were ER-beta positive and 58 (18.5 %) were HER2 positive. Among the 58 HER2 positive patients, 44 were ER-beta positive and 14 were ERbeta negative. ER-beta positive was associated with HER2 positive (75.9%, P=0.018) as well as ER-alpha positive (79.7%, P=0.023), poor cell differentiation (77.2% grade 2 or 3, P=0.010) and menopause age <45 yr (55.3%, P=0.031). HER2 positive was associated with poor cell differentiation (93.1%, P=0.001), ≥3cm tumour size (67.2%, P=0.011). Conclusion: Both ER-beta positive and HER2 positive status was associated with poorer overall survival (OS) by univariate analysis. In both HER2 positive and HER2 negative subgroups, ER-beta positive was associated with poorer distant disease free survival (DDFS) but not OS, which implied that ER-beta might relate to metastasis in breast cancer.
ACCESSION #
42093370

 

Related Articles

  • P53 nuclear accumulation and ERα expression in ductal hyperplasia of breast in a cohort of 215 Chinese women. Xiao-yun Mao; Chui-feng Fan; Hua-chuan Zheng; Jing Wei; Fan Yao; Feng Jin // Journal of Experimental & Clinical Cancer Research (17569966);2010, Vol. 29, p112 

    Introduction: Women with ductal hyperplasia including usual ductal hyperplasia (UDH) and atypical ductal hyperplasia (ADH) have an increased risk of developing invasive ductal carcinoma (IDC) of breast. The importance of several molecular markers in breast cancer has been of considerable...

  • Zip out cancer.  // New Scientist;1/4/2003, Vol. 177 Issue 2376, p20 

    Presents research conducted by Wen Jian and his team at University of Wales College in Cardiff, Wales which found the susceptibility of women with breast cancer to developing secondary tumors. Function of molecules called tight junctions in patients vulnerable to cancer.

  • NILCO biomarkers in breast cancer from Chinese patients. Colbert, Laronna S.; Wilson, Kaamilah; Sungjin Kim; Yuan Liu; Oprea-Ilies, Gabriela; Gillespie, Corey; Dickson, Toi; Newman, Gale; Gonzalez-Perez, Ruben Rene // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background: Notch, IL-1 and leptin are known pro-angiogenic factors linked to breast cancer development, tumor aggressiveness and poor prognosis. A complex crosstalk between these molecules (NILCO) has been reported in breast cancer cell lines. However, whether NILCO biomarkers are...

  • The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer. Michael Wirtenberger; Julia Schmutzhard // Carcinogenesis;Feb2007, Vol. 28 Issue 2, p423 

    Overexpression of cAMP-dependent protein kinase A (PKA) is a hallmark of the great majority of human cancers including breast cancer. A-kinase anchoring proteins (AKAPs) coordinate the specificity of PKA signalling by localizing the kinase to its subcellular sites. We tested the hypothesis...

  • Aromatase inhibition in male breast cancer patients: biological and clinical implications. Doyen, J.; Italiano, A.; Largillier, R.; Ferrero, J.-M.; Fontana, X.; Thyss, A. // Annals of Oncology;Jun2010, Vol. 21 Issue 6, p1243 

    Background: The role of aromatase inhibitors (AIs) and their impact on estradiol (E2) levels remain unknown in male breast cancer (MBC) patients.

  • Venlafaxine and Hot Flushes in Breast Cancer Survivors. Walling, Anne D. // American Family Physician;6/15/2001, Vol. 63 Issue 12, p2460 

    Presents information on a study by C. Loprinzi and others on the effect of venlafaxine on hot flushes in breast cancer survivors. Description of the study and its results; Conclusion that venlafaxine provides an effective treatment for hot flushes in women who are unwilling or unable to take...

  • Correcting for Lead Time and Length Bias in Estimating the Effect of Screen Detection on Cancer Survival. Stephen W. Duffy; Iris D. Nagtegaal; Matthew Wallis; Fay H. Cafferty; Nehmat Houssami; Jane Warwick; Prue C. Allgood; Olive Kearins; Nancy Tappenden; Emma OSullivan; Gill Lawrence // American Journal of Epidemiology;Jul2008, Vol. 168 Issue 1, p98 

    Determination of survival time among persons with screen-detected cancer is subject to lead time and length biases. The authors propose a simple correction for lead time, assuming an exponential distribution of the preclinical screen-detectable period. Assuming two latent categories of tumors,...

  • Circulating tumor cells may have predictive, prognostic value.  // Hem/Onc Today;1/25/2011, Vol. 12 Issue 2, p16 

    The article discusses research being done on the significance of the presence of circulating tumor cells in breast cancer patients.

  • Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. Hoadley, Katherine A.; Siegel, Marni B.; Kanchi, Krishna L.; Miller, Christopher A.; Ding, Li; Zhao, Wei; He, Xiaping; Parker, Joel S.; Wendl, Michael C.; Fulton, Robert S.; Demeter, Ryan T.; Wilson, Richard K.; Carey, Lisa A.; Perou, Charles M.; Mardis, Elaine R. // PLoS Medicine;1/9/2017, Vol. 14 Issue 1, p1 

    [This corrects the article DOI: 10.1371/journal.pmed.1002174.].

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics